This cluster groups 2 independently calculated changes: Cash & equivalents increased 2.2%; Operating cash flow increased 40.3%.
2 evidence-backed components· Pharmaceutical Preparations
RESEARCH SNAPSHOTPrelude Therapeutics Inc's latest supported as-filed period reports revenue of $5.7M. Every value below links to its SEC accession and metric lineage.
The most important deterministic changes, ranked by magnitude, issuer history, persistence, and accounting profile.
This cluster groups 2 independently calculated changes: Cash & equivalents increased 2.2%; Operating cash flow increased 40.3%.
2 evidence-backed componentsCurrent assets changed +101.5% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes. This reverses 4 consecutive comparable moves in the opposite direction.
Each point keeps the date investors could first observe it and its accession.
PRLD · as filed with the SEC · reported-date aware
Direct SEC links, filing dates, report periods, and amendment flags.
0001193125-26-387232SEC ↗10-QAug 11, 2026Period Jun 30, 20260001193125-26-343475SEC ↗8-KAug 11, 2026Period Aug 11, 20260001193125-26-343469SEC ↗4Jun 10, 2026Period Jun 9, 20260001193125-26-265965SEC ↗4Jun 10, 2026Period Jun 9, 20260001617541-26-000005SEC ↗4Jun 10, 2026Period Jun 9, 20260001435618-26-000006SEC ↗4Jun 10, 2026Period Jun 9, 20260001572451-26-000003SEC ↗Transaction semantics distinguish purchases, sales, awards, exercises, withholding, and derivatives.
GrossPattern stores immutable raw artifacts, accession-scoped facts, parser and metric versions, dependency edges, quality state, and channel-specific publication rights. A restricted or unknown ancestor blocks the page and API automatically.
SEC source policy ↗Total assets changed +64.8% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes. This reverses 4 consecutive comparable moves in the opposite direction.
Working capital changed +108.8% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes. This reverses 4 consecutive comparable moves in the opposite direction.
Free-cash-flow proxy changed +40.3% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
Operating cash flow changed +40.3% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes.
Shares outstanding changed +41.0% from the comparable as-filed period. The change ranks at the 88th percentile of 8 prior comparable changes.
Capital expenditure changed -100.0% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
Method note “Materiality” here is an analytical magnitude band, not a legal conclusion. Full filing-text semantic changes remain unpublished while excerpt rights and review thresholds are unresolved.
Latest supported period in this snapshot: 2026-06-30. Duration facts use direct quarterly or annual SEC contexts; GrossPattern does not manufacture missing Q4 values.
0001620368-26-000003